Results 211 to 220 of about 208,148 (266)

Total psoriasis regression in a patient with chronic myeloid leukemia treated using nilotinib. [PDF]

Ann Hematol
Horňák T, Žáčková D, Mayer J.
europepmc   +1 more source

Predicting drug resistance. [PDF]

Elife
Arellano NS, Elf SE.
europepmc   +1 more source

Bosutinib for Successful Treatment-Free Remission in Chronic Myeloid Leukemia. [PDF]

Cancer Med
Fujioka Y, Abumiya M, Ono T, Takahashi N.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population

Annals of Hematology, 2012
Cytogenetic analyses of chronic myelogenous leukemia (CML) have been performed previously in a large number of reports, but systematical research based on large sample sizes from the Chinese population is seldom available. In this study, we analyzed the cytogenetic profiles of 1,863 Philadelphia (Ph)/BCR-ABL-positive CML patients from a research center
Qitian Mu, Jie Jin, Ying Lu, Xiangmin Tong, Feifei Chen, Zhimei Chen, Yungui Wang, Qiuling Ma, Qiuling Ma   +8 more
openaire   +3 more sources

Cytogenetic response to autografting in chronic myelogenous leukemia correlates with the amount of BCR-ABL positive cells in the graft

Experimental Hematology, 2000
An important step in successful autografting of patients with chronic myelogenous leukemia is the delivery of a leukemia-free graft. We conducted this study to determine whether the cytogenetic response after autografting was correlated with the number of BCR ABL-positive cells present within the stem cell grafts.By BCR-ABL mRNA quantification, we ...
Monica Abate, F Vassallo, Cristina Parodi, Silvia Luchetti, Giuseppina Li Pira, Fabrizio Manca, Giovanna Piaggio, Angelo Michele Carella, Marina Cavaliere, O. Figari, Enrica Lerma, A. Dejana, Maria Teresa Corsetti   +12 more
openaire   +4 more sources

Presence or Re-Appearance of BCR-ABL-Positive Cells Years after Allogeneic Bone Marrow Transplantation for Chronic-Phase Chronic Myelogenous Leukemia in Patients in Hematological Remission

Acta Haematologica, 1994
Allogeneic bone marrow transplantation (BMT) is considered to be the only curative therapy for chronic myelogenous leukemia (CML). The cytogenetic marker of CML, the Philadelphia (Ph) chromosome, or the molecular alterations caused by the BCR-ABL gene fusion can be used to monitor the success of treatment.
U.W. Schaefer, R. Bützler, K. Quabeck, L. Diekmann, Reinhard Becher, H. Schulte Holthausen, B. Opalka, Dietrich W. Beelen   +7 more
openaire   +4 more sources

The Relationship Between the Type ofbcr-ablHybrid Messenger RNA and Thrombopoiesis in Philadelphia-Positive Chronic Myelogenous Leukemia

Leukemia & Lymphoma, 1993
Formation of the Philadelphia (Ph1) chromosome, which contains the hybrid bcr-abl gene, is thought to be the initial event in chronic myelogenous leukemia (CML). The positions of the breakpoint within the breakpoint cluster region (bcr) on the bcr-abl gene in 22 chronic-phase cases of Ph1-positive CML were determined using conventional Southern blots ...
Takeo Nomura, Koiti Inokuchi
openaire   +4 more sources

Human medicines European public assessment report (EPAR): IntronA, interferon alfa-2b, Carcinoid Tumor,Leukemia, Hairy Cell,Lymphoma, Follicular,Hepatitis B, Chronic,Hepatitis C, Chronic,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Melanoma,Multiple Myeloma, Date of authorisation: 09/03/2000, Revision: 31, Status: Authorised

Case Medical Research, 2019
semanticscholar   +3 more sources

Human medicines European public assessment report (EPAR): Sprycel, dasatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma,Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Date of authorisation: 20/11/2006, Revision: 32, Status: Authorised

Case Medical Research, 2019
semanticscholar   +3 more sources